Supernus touts ADHD Phase III data, but results appear to fall short of expectations
CNS-focused Supernus Pharmaceuticals $SUPN reported positive data from keenly watched twin studies testing its non-stimulant ADHD drug in children on Thursday, but the results suggested the treatment does not have a leg up over an existing generic drug on the market.
Shares of the Rockville, Maryland based-company were down about 13% in early trading.
Two doses of the drug SPN-812 were tested against a placebo in each study — 100mg/200mg in study P301, and 200mg/400 mg in study P303.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.